Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.61 |
| ▸ | PTGES | O14684 | 2/20 | 0.61 |
| ▸ | PPARA | Q07869 | 7/20 | 0.50 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CTRC | Q99895 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1565567 | 0.89 | PPARG (0.61) | PPARGALOX5PTGESPPARAALDH2 | |
| SCHEMBL1564807 | 0.87 | PPARA (0.59) | PPARGALOX5PTGESPPARAALDH2 | |
| SCHEMBL5053288 | 0.86 | FOLH1 (0.59) | PPARGALOX5PTGESPPARAFOLH1 | |
| SCHEMBL9092823 | 0.84 | PPARG (0.55) | PPARGALOX5PTGESPPARAALDH2 | |
| SCHEMBL1565583 | 0.82 | PPARG (0.53) | PPARGALOX5PTGESPPARAALDH2 | |
| SCHEMBL11854295 | 0.81 | CTRC (0.58) | PPARGALOX5PTGESPPARAALDH2 | |
| SCHEMBL14293619 | 0.80 | PPARG (0.54) | PPARGALOX5PTGESPPARAALDH2 | |
| SCHEMBL289442 | 0.80 | PPARG (0.64) | PPARGALOX5PTGESPPARAFOLH1 | |
| SCHEMBL8935884 | 0.80 | PPARG (0.64) | PPARGALOX5PTGESPPARAFOLH1 | |
| SCHEMBL21991463 | 0.79 | PPARG (0.50) | PPARGALOX5PTGESPPARAALDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305648-A1 | Amide derivatives useful as glucokinase activators | Novo Nordisk A/S (DK) | 2011-04-06 | — | — | EP | disclosed |
| EP-1458382-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| US-20030171411-A1 | Amide derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2003-09-11 | — | — | US | disclosed |
| EP-1336607-A1 | Amide derivatives as glucokinase activators | NOVO NORDISK A/S (DK) | 2003-08-20 | — | — | EP | disclosed |
| WO-2003055482-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171411-A1 | Amide derivatives as therapeutic agents | GK, GCKR, GCK | PPARG 75/4885ALOX5 1876/4885PTGES 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.